

해외 바이오의약품 임상 현황 (2020.05.18~2020.05.24)

한국바이오의약품협회, 2020.5.26.
출처: ClinicalTrials.gov

○ 미국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04399980	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	COVID 19 SARS-CoV 2 Pneumonia	Drug: Mavrilimumab Drug: Placebos	The Cleveland Clinic Kiniksa Pharmaceuticals, Ltd.	Phase 2
NCT04398706	Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants	Pneumococcal Immunisation Diphtheria Immunisation Tetanus Immunisation Pertussis Immunisation Hepatitis B Immunisation Haemophilus Influenzae Type b Immunisation Polio Immunisation Measles Immunisation Rubella Immunisation Varicella Immunisation Mumps Immunisation	Biological: SP0202-IIb Pneumococcal Conjugate Vaccine formulation 1 Biological: SP0202-VI Pneumococcal Conjugate Vaccine formulation 2 Biological: SP0202-VII Pneumococcal Conjugate Vaccine formulation 3 Biological: Varicella Virus Vaccine Live Biological: Measles, Mumps, and Rubella Virus Vaccine Live Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Biological: Rotavirus Vaccine, Live, Oral, Pentavalent Biological: Hepatitis B Vaccine [Recombinant]	Sanofi	Phase 2
NCT04386616	A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTR1147A in Patients With Severe COVID-19 Pneumonia	COVID-19 Pneumonia	Drug: MSTT1041A Drug: MSTT1041A-matched Placebo Drug: UTR1147A Drug: UTR1147A-matched Placebo	Genentech, Inc.	Phase 2
NCT04339413	A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 3
NCT04309474	A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke	Acute Ischemic Stroke	Drug: Elezanumab Drug: Placebo	AbbVie	Phase 2
NCT04205968	Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers	Metastatic Small Intestinal Adenocarcinoma Stage III Small Intestinal Adenocarcinoma AJCC v8 Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 Stage IV Small Intestinal Adenocarcinoma AJCC v8	Drug: Fluorouracil Drug: Irinotecan Drug: Irinotecan Hydrochloride Drug: Leucovorin Drug: Leucovorin Calcium Drug: Paclitaxel Biological: Ramucirumab	Southwest Oncology Group National Cancer Institute (NCI)	Phase 2

○ 영국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04393246	multi-Arm Therapeutic Study in Pre-ICU Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)	COVID-19	Drug: EDP1815 Drug: Dapagliflozin Drug: Ambrisentan Other: Standard of care	Cambridge University Hospitals NHS Foundation Trust	Phase 2 Phase 3
NCT04339413	A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)	Alzheimer Disease	Drug: Gantenerumab	Hoffmann-La Roche	Phase 3

○ 중국 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04383574	Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)	COVID-19	Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Other: Two doses of placebo at the schedule of day 0,28	Sinovac Research and Development Co., Ltd. Sinovac Biotech Co., Ltd	Phase 1 Phase 2
NCT04353830	A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors	Advanced Malignancies	Drug: IBI939 Drug: IBI939+ Sintilimab	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04100772	Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above	Pneumococcal Infections Streptococcal Infections Bacterial Infections	Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT) Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine	CanSino Biologics Inc. Henan Center for Disease Control and Prevention	Phase 1
NCT04385550	A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma	Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma	Drug: Anlotinib hydrochloride capsule Drug: AK105 injection Drug: Paclitaxel injection Drug: Docetaxel injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
NCT04194203	A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)	Carcinoma, Non-Small-Cell Lung	Drug: Atezolizumab Drug: Placebo Drug: Bevacizumab Drug: Paclitaxel Drug: Pemetrexed Drug: Carboplatin	Hoffmann-La Roche	Phase 3